Lexston Life Sciences Launches Tryptamine Pipeline Research
Vancouver, British Columbia -- September 23, 2021 -- NewsGenie -- Lexston Life Sciences Corp. (CNSX:LEXT.CN) has announced that its R&D division, under Chief Science Officer Dr. Philippe Henry, has commenced work on its tryptamine pipeline, initially focusing on 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) at Zenalytic Laboratories.
Following confirmation from Health Canada, Lexston's scientists are developing methods for identifying and quantifying 5-MeO-DMT. The company has successfully developed a High Pressure Liquid Chromatography (HPLC) assay for determining the purity of 5-MeO-DMT and has collected Near-Infrared spectra (NIRs) for rapid identification of tryptamine formulations.
Lexston is exploring botanical sources of 5-MeO-DMT and different delivery systems for a sub-psychoactive dosage formulation, intended for the alternative treatment of migraines and cluster headaches due to its neuro-vasocontraction abilities. The team is also gathering serotonin and receptor affinity data for 5-MeO-DMT and related tryptamines, expecting to uncover potential treatments for major depressive disorders and addiction, due to the molecules interaction with serotonin receptors 5HT-1a,7,6,1d and dopamine D1.
Graeme Staley, Director of Lexston, stated that the 5-MeO pathway is fundamental to developing novel treatments.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is securing licensing to expand its services into the psychedelic industry with a focus on the detection and quantification of psychedelic molecules and standardized manufacturing of plant derived psychedelics.